New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses

Human Gene Therapy

Volumn 9, Issue 13, 1998, Pages 1909-1917

  Fallaux, Frits J ^a   Bout, Abraham ^b   Van Der Velde, Ietje ^a   Van Den Wollenberg, Diana J M ^a   Hehir, Kathleen M ^c   Keegan, Jesse ^c   Auger, Crys ^c   Cramer, Steve J ^a   Van Ormondt, Hans ^a   Van Der Eb, Alex J ^a   Valerio, Dinko ^a,b   Hoeben, Rob C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOGLYCERATE KINASE;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CLONING VECTOR; COST EFFECTIVENESS ANALYSIS; GENE THERAPY; HELPER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; RAT; SEROTYPE; VIRUS RECOMBINATION; VIRUS REPLICATION;

EID: 17344373287     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.13-1909     Document Type: Article

References (16)

1. ARMENTANO, D., SOOKDEO, C.C., HEHIR, K.M., GREGORY, R.J., ST. GEORGE, J.A., PRINCE, G.A., WADSWORTH, S.C., and SMITH, A.E. (1995). Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6, 1343-1353.
2. ARMENTANO, D., ZABNER, J., SACKS, C., SOOKDEO, C.C., SMITH, M.P., ST. GEORGE, J.A., WADSWORTH, S.C., SMITH, A.E., and GREGORY, R.J. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71, 2408-2416.
3. BABISS, L.E., and VALES, L.D. (1991). Promoter of the adenovirus polypeptide IX gene: Similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. J. Virol. 65, 598-605.
4. BERNARDS, R., HOUWELING, A., SCHRIER, P.I., BOS, J.L., and VAN DER EB, A.J. (1982). Characterization of cells transformed by Ad5/Ad12 hybrid early region I plasmids. Virology 120, 422-432.
5. BERNARDS, R., SCHRIER, P.I., BOS, J.L., and VAN DER EB, AJ. (1983). Role of adenovirus types 5 and 12 early region 1b tumor antigens in oncogenic transformation. Virology 127, 45-53.
6. BETT, A.J., HADDARA, W., PREVEC, L., and GRAHAM, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91, 8802-8806.
7. - cells is activated by adenovirus region El A. EMBO J. 2, 73-76.
8. BOULANGER, P., LEMAY, P., BLAIR, G.E., and RUSSELL, W.C. (1979). Characterization of adenovirus protein IX. J. Gen. Virol. 44, 783-800.
9. BROUGH, D.E., LIZONOVA, A., HSU, C., KULESA, V.A., and KOVESDI, I. (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497-6501.
10. CARAVOKYRI, C., and LEPPARD, K.N. (1995). Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J. Virol. 69, 6627-6633.
11. COLBY, W.W., and SHENK, T. (1981). Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J. Virol. 39, 977-980.
12. DEBBAS, M., and WHITE, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546-554.
13. ESANDI, M.C., VAN SOMEREN, G.D., VINCENT, A.J., VAN BEKKUM, D.W., VALERIO, D., BOUT, A., and NOTEBOOM, J.L. (1997). Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther. 4, 280-287.
14. FALLAUX, F.J., KRANENBURG, O., CRAMER, S.J., HOUWELING, A., VAN ORMONDT, H., HOEBEN, R.C., and VAN DER EB, AJ. (1996). Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7, 215-222.
15. GALLIMORE, P.H., GRAND, R.J., and BYRD, P.J. (1986). Transformation of human embryo retinoblasts with simian virus 40, adenovirus and ras oncogenes. Anticancer Res. 6, 499-508.
16. GAO, G.P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.